• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register

SAR245409

Product ID S0269
Cas No. 1349796-36-6, 1123889-87-1
Purity ≥96%
Product Unit SizeCostQuantityStock
1 mg $119.90 In stock
5 mg $245.30 In stock
10 mg $436.00 In stock
25 mg $817.50 In stock
Bulk Quote
Add to Wishlist

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

SAR245409 is a pyridopyrimidinone derivative that inhibits PI3K and mTOR. This compound exhibits anticancer chemotherapeutic activity and shows benefit in clinical trials as a potential treatment for advanced solid tumors. SAR245409 inhibits cell proliferation and tumor growth in a variety of cancer models.

Product Info

Cas No.

1349796-36-6, 1123889-87-1

Purity

≥96%

Formula

C31H29N5O6S

Formula Wt.

599.66

Chemical Name

N-[4-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-3-methoxy-4-methylbenzamide

IUPAC Name

N-[4-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-3-methoxy-4-methylbenzamide

Synonym

XL765, Voxtalisib, SAR245409; XL-765; PI3K-IN-1; Voxtalisib analog

Solubility

DMSO 54 mg/mL (199.78 mM) Water Insoluble Ethanol Insoluble

Appearance

Off white to light yellow powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

S0269 MSDS PDF

Info Sheet

S0269 Info Sheet PDF

References

Yu P, Laird AD, Du X, et al. Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Impacting the PI3K Pathway. Mol Cancer Ther. 2014 Mar 19. [Epub ahead of print]. PMID: 24634413.

Papadopoulos K, Tabernero J, Markman B, et al. Phase I safety, pharmacokinetic and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors. Clin Cancer Res. 2014 Feb 28. [Epub ahead of print]. PMID: 24583798.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2023 LKT Laboratories, All Rights Reserved - Products for research use only